Last updated: September 5, 2026
Gamunex-C is the principal U.S. product matching the description “immune globulin injection (human) 10% caprylate/chromatography purified.” It is a plasma-derived 10% human immunoglobulin G product marketed by Grifols. Its commercial position is supported by established indications in primary immunodeficiency, immune thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy, rather than by long-lived small-molecule exclusivity.
The product’s financial trajectory depends on four variables: global demand for immunoglobulin, Grifols’ plasma-collection capacity, production yield and cost, and competition from other intravenous and subcutaneous immunoglobulin products. Gamunex-C has no conventional generic-entry profile. Its principal risks are supply expansion by competing plasma fractionators, payer-driven product substitution, subcutaneous immunoglobulin conversion and manufacturing constraints.
What product is immune globulin injection 10% caprylate/chromatography purified?
The product is Gamunex-C, a 10% liquid human immune globulin manufactured from pooled human plasma. The formulation uses caprylate precipitation and chromatography purification. Grifols acquired the product platform through its acquisition of Talecris Biotherapeutics in 2011.[1]
| Attribute |
Product detail |
| Brand |
Gamunex-C |
| Active ingredient |
Human immune globulin, predominantly IgG |
| Concentration |
10%, equivalent to 100 mg/mL |
| Manufacturer |
Grifols |
| Product type |
Plasma-derived biologic |
| U.S. regulatory pathway |
Biologics license application |
| U.S. application |
BLA 125122 |
| Principal routes |
Intravenous and subcutaneous, depending on indication and label |
| U.S. indications |
Primary humoral immunodeficiency, chronic ITP and CIDP |
| Dosage forms |
Single-use vials and prefilled or flexible infusion presentations, depending on market |
| Storage |
Refrigerated product with label-specific handling requirements |
Gamunex-C competes primarily with Privigen, Octagam, Panzyga, Flebogamma DIF and other human immunoglobulin products. The products are clinically similar in broad therapeutic use, but they are not automatically interchangeable at the product level. Physicians and payers consider indication, infusion tolerability, IgA content, excipients, supply reliability and route of administration.
How large is the immune globulin market?
The global immunoglobulin market is one of the largest segments of the plasma-derived therapeutics industry. Demand has expanded because of increased diagnosis of primary immunodeficiency, wider use in CIDP and neurologic disorders, population aging and greater access to immunoglobulin therapy in emerging markets.
The market is constrained by supply rather than demand alone. Manufacturers must collect, test, fractionate and purify large volumes of human plasma. The time required to expand plasma centers and qualify manufacturing capacity limits short-term supply growth.
What drives demand for Gamunex-C?
The main demand drivers are:
- Growth in diagnosed primary immunodeficiency patients.
- Continued use of IVIG in CIDP and immune-mediated neurologic disease.
- Expansion of home infusion and subcutaneous delivery.
- Increased use in countries with developing reimbursement systems.
- Product switching when competitors experience allocation or manufacturing interruptions.
CIDP is commercially important because treatment is chronic and recurring. Primary immunodeficiency also produces durable demand, although some patients transition from intravenous to subcutaneous therapy. ITP demand is more episodic and therefore less predictable.
How does Gamunex-C compare with competing immunoglobulin products?
Gamunex-C competes in both the hospital IVIG market and the home-infusion immunoglobulin market. The product’s caprylate/chromatography purification process is a differentiating manufacturing characteristic, but purchasing decisions are generally based on clinical familiarity, supply availability, contracting terms and route of administration.
| Product |
Company |
Primary commercial positioning |
Competitive relevance |
| Gamunex-C |
Grifols |
IVIG and selected subcutaneous use |
Established U.S. brand with broad physician familiarity |
| Privigen |
CSL Behring |
IVIG |
Strong hospital and specialty distribution presence |
| Hizentra |
CSL Behring |
Subcutaneous immunoglobulin |
Direct route-of-administration competitor |
| Panzyga |
Takeda |
IVIG |
Global expansion and hospital competition |
| Octagam |
Octapharma |
IVIG |
Broad international presence |
| Cutaquig |
Octapharma |
Subcutaneous immunoglobulin |
Home-infusion and self-administration competitor |
| Flebogamma DIF |
Grifols |
IVIG |
Internal portfolio competitor to Gamunex-C |
| HyQvia |
Takeda |
Facilitated subcutaneous immunoglobulin |
Competes for patients seeking less frequent administration |
The most important competitive distinction is not the active ingredient. It is delivery economics. IVIG typically requires a clinic, infusion center or hospital. Subcutaneous products can support home treatment and may reduce infusion-center utilization. Products such as Hizentra, Cutaquig and HyQvia therefore pressure IVIG demand in patients who are clinically suitable for home administration.
What is the FDA regulatory status of Gamunex-C?
Gamunex-C is an FDA-licensed biologic regulated under a BLA, not an approved small-molecule drug application. FDA labeling identifies primary immunodeficiency, ITP and CIDP as approved uses.[2]
The product’s principal regulatory characteristics are:
| Regulatory issue |
Status |
| FDA approval |
Licensed biologic |
| BLA |
125122 |
| Generic approval route |
Not applicable in the traditional ANDA sense |
| Biosimilar status |
No approved biosimilar equivalent identified in the FDA Purple Book for Gamunex-C |
| Interchangeability |
No automatic substitution framework comparable to conventional generic substitution |
| Orange Book listing |
Not the principal U.S. patent database for this product |
| Purple Book relevance |
Biologic reference-product and exclusivity information |
| Postapproval exposure |
Manufacturing, plasma supply, quality and pharmacovigilance obligations |
FDA biologic exclusivity is separate from the commercial life of the product. A reference biologic may retain significant market share after statutory exclusivity ends if competitors cannot replicate the manufacturing process, establish plasma supply or secure physician and payer adoption.
What patents protect Gamunex-C?
Gamunex-C is protected primarily by biologic manufacturing know-how, regulatory barriers, trademarks and operational scale rather than by a single publicly visible composition-of-matter patent.
The likely protection layers include:
- Purification and fractionation methods.
- Caprylate precipitation conditions.
- Chromatography parameters.
- Viral inactivation and removal processes.
- Plasma pooling and quality-control systems.
- Container, stability and filling processes.
- Product trademarks and regulatory history.
- Manufacturing-site qualifications and supply-chain relationships.
Unlike a conventional tablet, the active ingredient is pooled human IgG. A competitor cannot usually enter by copying a chemical structure and filing an ANDA. It must develop a separate biologic product, generate analytical and clinical evidence, secure plasma sources and obtain regulatory approval.
When does Gamunex-C lose exclusivity?
Gamunex-C does not have a single commercially decisive “patent cliff” comparable to a branded small molecule. Any original U.S. biologic exclusivity period has long expired, but that does not create an automatic generic launch opportunity. The relevant entry risk is a competing immune globulin biologic, not an ordinary generic.
Public regulatory materials do not establish a single patent expiration date that controls U.S. entry for Gamunex-C. Process patents may expire at different times, while manufacturing know-how and regulatory experience remain difficult to reproduce. The practical exclusivity period therefore extends beyond statutory data exclusivity.
Are there Paragraph IV challenges to Gamunex-C?
A conventional Paragraph IV challenge is unlikely to be the principal entry mechanism because Gamunex-C is licensed as a biologic under the Public Health Service Act. Paragraph IV litigation is associated mainly with ANDA applicants challenging Orange Book-listed patents for small-molecule drugs.
A competing biologic would generally pursue a biosimilar pathway under the Biologics Price Competition and Innovation Act. The applicant would face analytical similarity, manufacturing, immunogenicity and clinical evidence requirements. No approved biosimilar has displaced Gamunex-C in the U.S. market under a conventional interchangeable-generic model.
This does not eliminate litigation risk. Disputes may involve process patents, manufacturing patents, trademark rights, licensing obligations, supply agreements or alleged infringement by a follow-on biologic. The litigation economics differ from small-molecule patent litigation because the commercial barriers include production capability and regulatory approval.
How strong is the Gamunex-C patent estate?
The estate is commercially strong but legally different from a typical branded-drug estate.
| Protection category |
Strength |
Commercial effect |
| Composition patent |
Limited relevance for pooled human IgG |
Does not create a conventional molecule-level barrier |
| Manufacturing process |
Potentially meaningful |
Can complicate process replication |
| Plasma supply |
High practical value |
Limits the ability of new entrants to scale |
| Regulatory history |
High practical value |
Supports physician and payer confidence |
| Trademark |
Durable while maintained and enforced |
Protects brand recognition |
| Clinical familiarity |
Moderate to high |
Supports switching resistance |
| Biologic exclusivity |
Time-limited |
Historical barrier, not permanent |
| Distribution and contracts |
Market-dependent |
Can affect hospital access and conversion |
The strongest protection is operational. A competitor may reproduce a 10% IgG product in principle but still struggle to match yield, viral safety, batch consistency, delivery reliability and cost.
What manufacturing and supply barriers affect the product?
Plasma is the central bottleneck. Manufacturers depend on donor recruitment, collection-center throughput, testing, cold-chain logistics and fractionation capacity. Plasma collection disruptions can reduce market supply well before demand changes.
The manufacturing cost structure includes:
- Donor compensation and plasma-center operating expenses.
- Screening and infectious-disease testing.
- Fractionation and purification.
- Viral inactivation and removal.
- Quality-control testing and batch release.
- Cold-chain transportation.
- Regulatory compliance across multiple jurisdictions.
Scale provides an important advantage. Large fractionators can spread fixed manufacturing and compliance costs across a broader product portfolio. Grifols, CSL Behring, Takeda and Octapharma have structural advantages because they operate large plasma networks and established fractionation infrastructure.
What is the financial trajectory for Gamunex-C?
Grifols does not generally report Gamunex-C revenue as a standalone product line. The product is included within broader Biopharma or plasma-derived product reporting. Product-level sales, gross margin and operating profit are therefore not publicly separable from company filings.
Grifols reported consolidated revenue of approximately €6.6 billion in 2023, with Biopharma as its largest business area.[3] The company’s financial trajectory has been shaped by plasma-derived medicines, especially immunoglobulins, albumin and alpha-1 antitrypsin products. Growth has depended on volume recovery, plasma collection expansion, price and mix, and manufacturing productivity.
| Financial driver |
Effect on Gamunex-C economics |
| Immunoglobulin demand |
Supports volume growth |
| Plasma-center expansion |
Increases potential supply but raises near-term costs |
| Plasma yield |
Directly affects unit cost and capacity |
| Product mix |
Higher-value indications can improve revenue quality |
| Hospital contracting |
Can pressure net price |
| Subcutaneous conversion |
May shift demand away from IVIG |
| Supply interruptions |
Can increase demand and pricing for available product |
| Manufacturing efficiency |
Supports margin expansion |
| Foreign-exchange movements |
Affect reported Grifols revenue |
| Debt and interest expense |
Affect corporate earnings even when product demand remains strong |
Gamunex-C has attractive revenue characteristics because primary immunodeficiency and CIDP produce repeat treatment demand. The product also benefits when supply-constrained markets prioritize established manufacturers. Margin risk comes from high plasma costs, contract pricing and the need to maintain redundant manufacturing and quality systems.
The product is unlikely to experience a sudden revenue collapse from ordinary generic substitution. A more probable trajectory is gradual share pressure from competing IVIG products and migration to subcutaneous immunoglobulin, offset by market growth and supply-driven pricing.
What litigation and settlement risks affect Gamunex-C?
No widely reported Paragraph IV settlement framework governs Gamunex-C in the manner seen for major small-molecule drugs. The most relevant legal risks are:
- Process-patent disputes with competing biologic manufacturers.
- Biosimilar patent litigation under the BPCIA.
- Contract disputes with hospitals, specialty pharmacies or distributors.
- Manufacturing and quality claims.
- Product-liability and adverse-event litigation.
- Trademark or trade-dress disputes involving competing immune globulin products.
A biosimilar entrant would need to establish regulatory and commercial viability before litigation could materially change the market. The absence of an ANDA-style automatic substitution mechanism reduces the probability of an immediate, high-volume generic launch.
What generic entry risks exist for Gamunex-C?
The near-term generic-entry risk is low. The main competitive threats are:
- New plasma-derived IVIG capacity.
- Biosimilar or follow-on immunoglobulin products.
- Conversion to subcutaneous immunoglobulin.
- Payer-mandated product switching.
- Supply reliability improvements by CSL Behring, Takeda or Octapharma.
- Hospital purchasing consolidation.
- Lower-cost products in price-sensitive international markets.
The most credible launch scenario is a gradual share shift, not a patent-cliff event. A follow-on product that offers reliable supply, lower net pricing or a more convenient delivery system could win accounts even without automatic pharmacy substitution.
How does Gamunex-C compare with other Grifols products?
Gamunex-C and Flebogamma DIF are both Grifols immune globulin products, but they occupy overlapping commercial territory. Internal portfolio competition can allow Grifols to retain customers even when a hospital changes product preference. It can also create pricing pressure if buyers negotiate across the company’s product range.
Gamunex-C has greater importance in the U.S. specialty and neurologic markets because of its established label and physician familiarity. Flebogamma has broader international relevance in selected markets. The combined portfolio gives Grifols scale in plasma procurement, manufacturing and distribution.
What is the outlook for Gamunex-C?
Gamunex-C should remain a durable biologic franchise with moderate long-term growth potential and low conventional generic risk. Revenue growth is more likely to come from market expansion, treatment penetration and price-volume management than from new exclusivity.
The key downside risks are a fall in plasma availability, margin compression from donor-acquisition costs, stronger subcutaneous conversion and payer pressure on IVIG utilization. The principal upside drivers are sustained immunoglobulin demand, improved plasma yields, expanded treatment in CIDP and primary immunodeficiency, and reliable supply during competitor disruptions.
Key Takeaways
- Gamunex-C is the principal U.S. product matching immune globulin injection human 10% caprylate/chromatography purified.
- Grifols markets the product under BLA 125122.
- The product is a plasma-derived biologic, not a conventional small-molecule drug.
- No ordinary ANDA generic or automatic generic-substitution pathway applies.
- No single patent expiration date defines the product’s commercial life.
- Manufacturing know-how, plasma supply and regulatory infrastructure are more important than molecule-level patent protection.
- The main competitors are Privigen, Panzyga, Octagam, Flebogamma, Hizentra, Cutaquig and HyQvia.
- Gamunex-C benefits from recurring demand in primary immunodeficiency and CIDP.
- The product’s principal financial risks are plasma costs, hospital contracting, subcutaneous conversion and competitor supply expansion.
- Grifols does not publicly disclose standalone Gamunex-C revenue, so financial analysis must rely on company-level Biopharma results and market indicators.
FAQs
Is Gamunex-C the same as immune globulin 10%?
Yes. Gamunex-C is a 10% human immune globulin product, with 100 mg of IgG per mL. Products with the same concentration are not automatically interchangeable because formulation, manufacturing and regulatory status differ.
Is Gamunex-C a biosimilar?
No. Gamunex-C is the reference plasma-derived product marketed under its own biologics license. No approved U.S. biosimilar has established automatic substitution with Gamunex-C.
Can a generic company launch Gamunex-C after patent expiration?
No conventional generic launch is available through an ANDA. A competitor would need to develop and obtain approval for a separate biologic or follow-on product and build compliant plasma-derived manufacturing capacity.
Does Gamunex-C have an Orange Book patent listing?
The Orange Book is not the primary U.S. patent framework for Gamunex-C because it is a biologic licensed under a BLA. Biologic reference-product information is handled through FDA biologic records and the Purple Book, while patent disputes may arise under the BPCIA or other patent statutes.
Which company has the strongest competitive position against Gamunex-C?
CSL Behring is the strongest broad competitor because of its plasma network, Privigen IVIG franchise and Hizentra subcutaneous product. Takeda and Octapharma also have meaningful competitive positions through Panzyga, HyQvia, Octagam and Cutaquig.
References
- Grifols, S.A. (2011). Annual report 2011. Grifols.
- U.S. Food and Drug Administration. (2023). Gamunex-C prescribing information. FDA.
- Grifols, S.A. (2024). Annual report 2023. Grifols.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database, BLA 125122. FDA.
